CTI Life Sciences Fund’s Post

Fantastic series B fund raise to close out 2023! Exciting 2024 ahead for everyone at Sudo Biosciences as they take two of their best/first in class, next gen TYK2 inhibitors into clinic. #fundraise #researchanddevelopment #lifesciences #biotechnology #neurology #dermatology

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks

We are excited to announce the successful close of our £40.5 million Series A financing! We are very proud to welcome our new investors Pfizer Ventures LLC, who led the round, COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. and British Patient Capital. They were joined by our founding investor Advent Life Sciences, and seed investor Epidarex Capital, underlining strong blue chip confidence behind Curve Therapeutics' vision to transform the lives of patients by addressing disease targets which are intractable to conventional #drugdiscovery methods. The financing will enable Curve Therapeutics to turbocharge its Microcycle® discovery platform and advance its promising pipeline of assets with the potential to treat unmet clinical needs in a diverse range of diseases, including cancer. To learn more about the financing and our proprietary discovery platform, read the full press release here: https://lnkd.in/eRDFP2X6 #biotech #financing #investment

We are delighted to share the outstanding performance of Ally Bridge Group, one of our top-performing fund managers in the life sciences sector, which has successfully executed its fourth liquidity event since September 2023. Specializing in late-stage private equity, Ally Bridge Group is dedicated to significant investments in groundbreaking life science innovations aimed at fulfilling critical medical needs, primarily within the U.S. MedTech, biotech, diagnostics, and telehealth industries. Our firm has consistently supported Ally Bridge's previous funds and takes pride in their recent achievements in the U.S., highlighted by four notable liquidity events within the last five months: 𝟭. 𝗖𝗚 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 [𝗖𝗚𝗢𝗡.𝗡𝗮𝘀𝗱𝗮𝗾]: Listed on January 25, 2024, this company focuses on oncolytic immunotherapy for bladder cancer. Its IPO was nearly 20 times oversubscribed, with shares initially offered at $19 and closing at $37.26 after opening at a 96% increase, valuing the company at $2.2 billion. https://lnkd.in/dkMXjz4r    𝟮. 𝗖𝗮𝗿𝗴𝗼 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 [𝗖𝗥𝗚𝗫.𝗡𝗮𝘀𝗱𝗮𝗾]: Listed in November 2023, it is a clinical-stage biotech firm developing next-generation cell therapies for cancer. The IPO price was $15.00 per share, with a recent closing at $22.01. 𝟯. 𝗥𝗮𝘆𝘇𝗲𝗯𝗶𝗼 𝗜𝗻𝗰 [𝗥𝗬𝗭𝗕.𝗡𝗮𝘀𝗱𝗮𝗾]: Listed in September 2023, specializing in targeted radiopharmaceuticals for cancer treatment, was acquired by Bristol Myers Squibb on December 26, 2023, at $62.5 per share, compared to its IPO price of $18.00. https://lnkd.in/g7bcEkiZ 𝟰. 𝗥𝗲𝗹𝗶𝗲𝘃𝗮𝗻𝘁: Invested in March 2023, this medical device company focuses on treating chronic lower back pain and was acquired by Boston Scientific on November 17, 2023. https://lnkd.in/dhjGUJAC Congratulations to all our clients who have participated in these ventures. We look forward to further deploying capital into Ally Bridge’s follow-on fund, 'ABG V'.

It's no secret that I'm a big believer that #biotech is the investment wave of the 2020s. So, am I surprised that CG Oncology's IPO soared by 96% on its first day? Well, a little! Some #investors have been slow to adopt the biotech wave—especially when it's a brand-new IPO. But CG's success could point to increased (and much-deserved) interest in the field. Time will tell if CG Oncology can live up to these expectations. But one thing is clear: biotech #investments are growing in popularity. And I expect that trend to continue for at least the next several years. https://loom.ly/GNf7vvQ

𝐈𝐃𝐑𝐱'𝐬 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚𝐧 𝐨𝐯𝐞𝐫𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞𝐝 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 IDRx has announced the successful completion of an oversubscribed $120M Series B financing, led by RA Capital Management, Commodore Capital, and Blackstone Multi-Asset Investing. The funds will support the ongoing Phase 1/1b StrateGIST 1 study of IDRx's lead candidate, IDRX-42. Key highlights: • Fast Track designation granted by the U.S. FDA for IDRX-42. • Promising preliminary Phase 1 data, showing a 43% ORR in second-line GIST patients. • Strong backing from top-tier investors, including RA Capital, Andreessen Horowitz, and Merck KGaA. This milestone brings IDRx closer to its goal of transforming GIST treatment with precision therapies designed to address treatment resistance and adverse events. The company expresses its gratitude to the dedicated team, partners, and investors who continue to support its mission to elevate the standard of care for GIST patients. #Biotech #PrecisionMedicine #Oncology #GIST #ClinicalTrials 

...The Series B financing, which brought the total capital raised to approximately $200m, was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), #SheatreeCapital, Black Opal Ventures, Keller Williams Realty, Alexandria Ventures, LLC , and other undisclosed investors, and existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb, Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, Washington Research Foundation (WRF) Capital, and Sahsen Ventures, LLC Ventures. Jake Simson, PhD, Partner at RA Capital Management has been appointed to the company’s Board of Directors. Led by Marc Lajoie, PhD, Co-Founder & Chief Executive Officer, Outpace Bio is advancing an internal pipeline of engineered T cell therapies for the treatment of solid tumors.... #seriesB #solidtumors #200m #SeriesB144m #tcelltherapies #capital #celltherapy #cellandgenetherapy #CarT #regenerativemedicine #advancedtherapies #investment #AIpoweredproteindesign #AI #cellprogramming #biotech #biotechnology #pipeline #oncology #cancer #lifescience #lifesciences #therapeutics

Some positive news to end the week. J.P. Morgan actually launched its life sciences private capital team back in 2022 (lead by Regeneron and Alexion Pharmaceuticals, Inc. cofounder Stephen Squinto). What does the team plan to invest in? The article notes that investments will go toward biotechs of all stages, but obesity therapies, of course, along with treatments for cardiometabolic disease, immune-driven conditions, and more. #biotech #venture #financing #investments #lifesciences https://lnkd.in/etfMrSEd

The private equity manager TPG said Tuesday morning it closed a $580 million “Life Sciences Innovations” fund that will invest in about 15 to 20 companies. The new fund follows a $650 million fund at Goldman Sachs, a $500 million-plus fund at J.P. Morgan and about two dozen funds from biotech and life sciences specialists so far this year... ....Ng said in a statement that most of the fund’s capital will go into “preclinical and clinical-stage therapeutics companies.” Therapeutic areas can include oncology, I&I, cardiometabolic, ophthalmology and rare diseases. .... #biotech #biotechnology #lifescience #lifesciences #celltherapy #genetherapy #advancedtherapies #regenerativemedicine #funding #financing #earlystage #preclinicalfunding #clinicaltrials #clinicalstage #fundinggrowth #pipelinefunding #580m

📢 Funding News: £35 Million Series A Financing 📢 Today, we announce our Series A financing round led by Forbion, alongside our founding investors SV Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). The funds will be used to advance our small molecule somatic expansion inhibition therapy for Huntington’s disease. Our lead programme, MutSβ inhibitor is expected to enter the clinic in 2026. In connection with the financing, we welcome Rogier Rooswinkel, General Partner at Forbion to the LoQus23 Board of Directors. At LoQus23, we are investigating small molecule drugs that could stop #DNAinstability and slow #neurodegeneration in #HuntingtonsDisease. We look forward to progressing our pipeline with the support of our investors, so make sure you’re following LoQus23 Therapeutics Ltd on LinkedIn to stay up to date. 👉 Visit our new website to read the press release and find out more by using the link in the comments below. #financing #venturecapital #drugdevelopment #UKbiotech